The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers
暂无分享,去创建一个
O. Howes | M. Wall | M. Bloomfield | H. Curran | V. Curran | C. Hindocha | W. Lawn | T. Freeman | H. Walker | Y. Yamamori | S. Green | J. Yim | J. Hill | Gus Jones | H.
[1] G. Baio,et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. , 2020, The lancet. Psychiatry.
[2] G. Baio,et al. Cannabidiol for the treatment of cannabis use disorder: Phase IIa double-blind placebo-controlled randomised adaptive Bayesian dose-finding trial , 2020 .
[3] J. Rudd,et al. Fundamental Movement Skill Interventions , 2020 .
[4] S. Naveed,et al. The therapeutic role of Cannabidiol in mental health: a systematic review , 2020, Journal of Cannabis Research.
[5] M. Delgado,et al. Reward Processing , 2019 .
[6] Ninon Burgos,et al. New advances in the Clinica software platform for clinical neuroimaging studies , 2019 .
[7] Y. Hurd,et al. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. , 2019, The American journal of psychiatry.
[8] P. Griffiths,et al. Increasing potency and price of cannabis in Europe, 2006–16 , 2019, Addiction.
[9] S. O'Sullivan,et al. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans , 2018, Front. Pharmacol..
[10] B. Gidal,et al. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects , 2018, CNS Drugs.
[11] I. McGregor,et al. Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats , 2018, Journal of psychopharmacology.
[12] J. Roiser,et al. Neuroscience of apathy and anhedonia: a transdiagnostic approach , 2018, Nature Reviews Neuroscience.
[13] C. Morgan,et al. Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal , 2018, Addiction.
[14] M. Yücel,et al. The anticipation and outcome phases of reward and loss processing: A neuroimaging meta‐analysis of the monetary incentive delay task , 2018, Human brain mapping.
[15] T. Lovick,et al. Female psychopharmacology matters! Towards a sex-specific psychopharmacology , 2018, Journal of psychopharmacology.
[16] J. Manzanares,et al. Cannabidiol reduces ethanol consumption, motivation and relapse in mice , 2018, Addiction biology.
[17] P. McGuire,et al. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. , 2017, The American journal of psychiatry.
[18] S. Laviolette,et al. Adolescent THC Exposure Causes Enduring Prefrontal Cortical Disruption of GABAergic Inhibition and Dysregulation of Sub-Cortical Dopamine Function , 2017, Scientific Reports.
[19] James A Bisby,et al. Cannabis Dampens the Effects of Music in Brain Regions Sensitive to Reward and Emotion , 2017, The international journal of neuropsychopharmacology.
[20] M. Bloomfield,et al. The Acute Effects of a Dopamine D3 Receptor Preferring Agonist on Motivation for Cigarettes in Dependent and Occasional Cigarette Smokers , 2017, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[21] F. Guimarães,et al. Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life , 2017, Front. Pharmacol..
[22] M. Haney,et al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. , 2017, Drug and alcohol dependence.
[23] A. Zuardi,et al. Even High Doses of Oral Cannabidiol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al. Cannabis and Cannabinoid Research 2016;1(1):102–112; DOI: 10.1089/can.2015.0004 , 2017, Cannabis and cannabinoid research.
[24] N. Volkow,et al. The effects of Δ9-tetrahydrocannabinol on the dopamine system , 2016, Nature.
[25] K. Berridge,et al. Liking, wanting, and the incentive-sensitization theory of addiction. , 2016, The American psychologist.
[26] D. Nutt,et al. Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses , 2016, Psychopharmacology.
[27] G. Bedi,et al. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis , 2016, Neuropsychopharmacology.
[28] L. Parsons,et al. Keep off the grass? Cannabis, cognition and addiction , 2016, Nature Reviews Neuroscience.
[29] J. Merrick,et al. Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid , 2016, Cannabis and cannabinoid research.
[30] M. Goodale,et al. Equal-magnitude size-weight illusions experienced within and between object categories. , 2016, Journal of vision.
[31] L. Parsons,et al. Endocannabinoid signaling in reward and addiction , 2015 .
[32] P. McGuire,et al. Cannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience , 2015, Neuropsychopharmacology.
[33] C. Morgan,et al. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users , 2015, European Neuropsychopharmacology.
[34] M. Potenza,et al. Anticipatory Reward Processing in Addicted Populations: A Focus on the Monetary Incentive Delay Task , 2015, Biological Psychiatry.
[35] M. Treadway,et al. Reward processing dysfunction in major depression, bipolar disorder and schizophrenia , 2015, Current opinion in psychiatry.
[36] S. Machado,et al. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. , 2014, CNS & neurological disorders drug targets.
[37] A. Okely,et al. Fundamental Movement Skill Interventions in Youth: A Systematic Review and Meta-analysis , 2013, Pediatrics.
[38] Michael F. Green,et al. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. , 2013, Journal of psychiatric research.
[39] G. Panagis,et al. Cannabidiol inhibits the reward‐facilitating effect of morphine: involvement of 5‐HT1A receptors in the dorsal raphe nucleus , 2013, Addiction biology.
[40] N. Ramsey,et al. THC reduces the anticipatory nucleus accumbens response to reward in subjects with a nicotine addiction , 2013, Translational Psychiatry.
[41] R. Murray,et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment , 2013, Journal of psychopharmacology.
[42] P. McGuire,et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. , 2012, Current pharmaceutical design.
[43] M. Hellmich,et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia , 2012, Translational Psychiatry.
[44] Rita Z. Goldstein,et al. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications , 2011, Nature Reviews Neuroscience.
[45] N. Ramsey,et al. Involvement of the endocannabinoid system in reward processing in the human brain , 2011, Psychopharmacology.
[46] R. Roesler,et al. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients , 2011, Neuropsychopharmacology.
[47] J. Roiser,et al. Reward and Punishment Processing in Depression , 2010, Biological Psychiatry.
[48] G. Schafer,et al. Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis , 2010, Neuropsychopharmacology.
[49] R. Murray,et al. Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology , 2010, Neuropsychopharmacology.
[50] Y. Hurd,et al. Cannabidiol, a Nonpsychotropic Component of Cannabis, Inhibits Cue-Induced Heroin Seeking and Normalizes Discrete Mesolimbic Neuronal Disturbances , 2009, The Journal of Neuroscience.
[51] Jeffrey N. Rouder,et al. Bayesian t tests for accepting and rejecting the null hypothesis , 2009, Psychonomic bulletin & review.
[52] M. Jaber,et al. Environmental Enrichment During Early Stages of Life Reduces the Behavioral, Neurochemical, and Molecular Effects of Cocaine , 2009, Neuropsychopharmacology.
[53] J. W. Aldridge,et al. Dissecting components of reward: 'liking', 'wanting', and learning. , 2009, Current opinion in pharmacology.
[54] P. Fusar-Poli. Distinct Effects of D9-tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing , 2009, European Psychiatry.
[55] H. Heinze,et al. Mesolimbic Functional Magnetic Resonance Imaging Activations during Reward Anticipation Correlate with Reward-Related Ventral Striatal Dopamine Release , 2008, The Journal of Neuroscience.
[56] Brian Knutson,et al. Anticipatory affect: neural correlates and consequences for choice , 2008, Philosophical Transactions of the Royal Society B: Biological Sciences.
[57] J. Waltz,et al. Reward processing in schizophrenia: a deficit in the representation of value. , 2008, Schizophrenia bulletin.
[58] Brian Knutson,et al. Neural Responses to Monetary Incentives in Major Depression , 2008, Biological Psychiatry.
[59] Camelia M. Kuhnen,et al. Nucleus accumbens activation mediates the influence of reward cues on financial risk taking , 2008, Neuroreport.
[60] R. Pertwee,et al. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .
[61] E. Nestler,et al. The Mesolimbic Dopamine Reward Circuit in Depression , 2006, Biological Psychiatry.
[62] Arno Villringer,et al. Dysfunction of ventral striatal reward prediction in schizophrenia , 2006, NeuroImage.
[63] S. Kapur,et al. From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis , 2005, Schizophrenia Research.
[64] E. Russo,et al. Agonistic Properties of Cannabidiol at 5-HT1a Receptors , 2005, Neurochemical Research.
[65] R. Mechoulam,et al. Effect of low doses of Δ9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats , 2004, Psychopharmacology.
[66] Brian Knutson,et al. Anticipation of Increasing Monetary Reward Selectively Recruits Nucleus Accumbens , 2001, The Journal of Neuroscience.
[67] M. Christ,et al. Acute effects of a single oral dose of carvedilol on cardiac sympathovagal balance in man. , 2001, International journal of clinical pharmacology and therapeutics.
[68] T. G. Burns,et al. BOOK AND TEST REVIEW , 2000 .
[69] Brian Knutson,et al. FMRI Visualization of Brain Activity during a Monetary Incentive Delay Task , 2000, NeuroImage.
[70] Environmental enrichment , 1996, Animal Welfare.
[71] O. Aasland,et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. , 1993, Addiction.
[72] F. Graeff,et al. Effects of ipsapirone and cannabidiol on human experimental anxiety , 1993, Journal of psychopharmacology.
[73] S. Snider,et al. Controlled clinical trial of cannabidiol in Huntington's disease , 1991, Pharmacology Biochemistry and Behavior.
[74] L. Kozlowski,et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. , 1991, British journal of addiction.
[75] D. Jackson,et al. The effect of cannabidiol, alone and in combination with ethanol, on human performance , 1979, Psychopharmacology.
[76] D. Pizzagalli,et al. Blunted neural responses to reward in remitted major depression: A high-density event-related potential study. , 2016, Biological psychiatry. Cognitive neuroscience and neuroimaging.
[77] Guillermo I Carrillo,et al. A Controlled Clinical Trial , 2015 .
[78] Thomas M Seed,et al. Acute Effects , 2011 .
[79] T. Insel. Rethinking schizophrenia , 2010, Nature.
[80] S. Haber,et al. The Reward Circuit: Linking Primate Anatomy and Human Imaging , 2010, Neuropsychopharmacology.
[81] P. McGuire,et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. , 2009, Archives of general psychiatry.
[82] R. Pertwee. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids : D 9-tetrahydrocannabinol , cannabidiol and D 9-tetrahydrocannabivarin , 2007 .
[83] M. First,et al. Structured clinical interview for DSM-IV axis II personality disorders : SCID-II , 1997 .